,i #aaith ,,congress #b;d ,session ,h4 ,r4 #gaah ,,in ,,the ,,house ,,of ,,representatives ,january #ae1 #bjbf,mr4 ,peters 7for himself1 ,mr4 ,bilirakis1 ,mr4 ,veasey1 ,mr4 ,balderson1 ,mr4 ,mullin1 ,mr4 ,carey1 ,ms4 ,houlahan1 and ,ms4 ,salazar7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend title ,,xix of the ,social ,security ,act to clarify that whole genome and whole exome sequencing for children with certain medical needs is covered under the ,medicaid program4 #a4 ,short title ,this ,act may be cited as the ,genomic ,answers for ,children's ,health ,act of #bjbf4 #b4 ,clarifying that whole genome and whole exome sequencing for children with certain medical needs is covered under the ,medicaid program 7a7 ,in general ,section #aije of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;d7 is amended-- 7#a7 in subsection 7r7-- 7,a7 by redesignating paragraph 7#e7 as paragraph 7#f72 and 7,b7 by inserting after paragraph 7#d7 the following new paragraph3 7#e7 ,whole genome sequencing and whole exome sequencing 7as defined in subsection 7kk771 whether furnished in the inpatient or outpatient setting1 if ordered by a physician or other provider acting within the provider's scope of practice under ,state law as a first-tier test for an individual suspected to have a genetic disorder1 rare disease1 or a health condition of unknown origin1 including #a or more congenital anomalies1 a global developmental delay1 or an intellectual disability4 2 and 7#b7 by adding at the end the following new subsection3 7kk7 ,whole genome sequencing and whole exome sequencing ,for purposes of subsection 7r77#e71 the term whole genome sequencing and whole exome sequencing-- 7#a7 means the determination of a sequence of deoxyribonucleic acid bases in the genome taken or derived from an individual1 and1 if for the primary benefit of the individual's diagnosis or treatment1 a first degree biological relative or relatives of such individual for the purpose of determining whether #a or more potentially disease-causing genetic variants are present in the genome of such individual or such biological first-degree relative2 and 7#b7 includes-- 7,a7 the sequencing of the whole genome or the whole exome2 and 7,b7 any analysis1 interpretation1 and data report derived from such sequencing4 4 7b7 ,additional updates ,section #aijb7;a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;a7a77 is amended-- 7#a7 in paragraph 7#hh71 by striking and at the end2 7#b7 in paragraph 7#hi71 by striking the period and inserting 2 and2 and 7#c7 by inserting after paragraph 7#hi7 the following new paragraph3 7#ij7 provide that payment for whole genome sequencing and whole exome sequencing 7as defined in section #aije7kk77 is made separately and is not bundled as part of payment for any other medical assistance4 4 7c7 ,outreach and education ,for purposes of promoting awareness of and access to whole genome and exome sequencing under section #aije7r7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;d7r771 the ,secretary of ,health and ,human ,services shall-- 7#a7 convene national organizations 7including at least those organizations representing pediatricians1 specialists in pediatric rare diseases1 children's hospitals1 geneticists1 genetic counselors1 laboratory test developers71 ,states1 hospitals and health systems1 individuals with rare diseases1 and those national organizations representing ,medicaid managed care organizations to identify challenges and opportunities in implementation of the amendments made by this section1 including potential best practices that minimize denials of claims for medical assistance under the ,state plan under title ,,xix of such ,act resulting from use of prior authorization or administrative requirements2 7#b7 conduct outreach to national organizations 7including at least those organizations representing hospitals1 health systems1 children's hospitals1 pediatricians1 and geneticists71 ,states1 national organizations representing ,medicaid managed care oganizations1 national organizations representing rare disease patients and families1 and national organizations representing ,medicaid-eligible children and their families to ensure they are aware of the early and periodic screening1 diagnostic1 and treatment services benefit under title ,,xix of such ,act and can benefit from access to required screenings and necessary treatment services2 and 7#c7 not later than #b years after the date of the enactment of this ,act1 publish on the public website of the ,department of ,health and ,human ,services a report that includes-- 7,a7 payment amounts for whole genome sequencing and whole exome sequencing under each ,state plan under title ,,xix of such ,act2 and 7,b7 information relating to the number of children receiving such sequencing under such ,state plans1 health outcomes1 types of services provided as a result of such sequencing1 and other such relevant information4 7d7 ,report ,not later than #b years after the date of the enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall do the following3 7#a7 ,collect and analyze feedback regarding implementation of the amendments made by this ,act from the organizations and entities described in paragraph 7#a7 or 7#b7 of subsection 7b71 including-- 7,a7 experiences in accessing whole genome sequencing and whole exome sequencing and results pursuant to such amendments1 including any barriers to such access2 7,b7 changes to care or services furnished after such sequencing2 7,c7 identification of remaining challenges1 if any1 related to access to such sequencing for individuals eligible for early and periodic screening1 diagnostic1 and treatment services under the ,medicaid program2 and 7,d7 health professional awareness of such amendments4 7#b7 ,assess the following for impacts on access to such sequencing under such program for such individuals3 7,a7 ,prior authorization1 which may include assessment of impacts related to delay of care and uncertainty or surprise of payment4 7,b7 ,workforce and reimbursement challenges for genetic counselors4 7,c7 ,the extent to which market cost is aligned with the ,medicare clinical laboratory fee schedule and the degree to which the ,secretary of ,health and ,human ,services' adjustment of the fee schedule might more accurately reflect market realities and support affordability4 7#c7 ,make recommendations to the ,secretary of ,health and ,human ,services relating to additional guidance or improvements that may be made based on the feedback collected under paragraph 7#a7 and the assessment described in paragraph 7#b74 7e7 ,effective date ,the amendments made by this section shall apply beginning ,january #a1 #bjbg4